Patients with ICCs demonstrating negative or weak expression of syndecan-1 frequently had lymph node metastases and had a rather poor prognosis after surgical resection compared with those whose tumors demonstrated moderate or strong expression (P <0.05).
Multivariate analysis showed SDC (p = .002) to be the strongest predictor of lymph node metastasis, followed by MET aberration (p = .009), T3/T4 classification (p = .017), PTEN deletion (p = .042), and adenocarcinoma not otherwise specified (NOS; p = .047).
Loss of SDC1 protein expression is associated with poor overall (<i>p</i> < 0.0001) and disease-free survival (<i>p</i> < 0.0001), differentiation (<i>p</i> = 0.017), stage (<i>p</i> ≤ 0.001), and lymph node metastasis (<i>p</i> ≤ 0.001) in CRC patients.
The decreased expression of Syndecan-1 mRNA and the increased expression of HPA-1 were closely associated with the degree of differentiation, the depth of infiltration, lymph node metastasis, vessel metastasis, and TNM staging of colorectal cancer (all P < 0.05).